BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

BRAIN Biotech AG

Biocatalysts is a biotechnology company that produces specialty enzymes at commercial scales for various industries. It offers a range of technical, commercial, and regulatory capabilities to enhance value for its customers, self-described as developing biobased value.

Biocatalysts

BRAIN Biotech AG specializes in industrial biotechnology, focusing on providing sustainable products and processes through optimized enzymes, high-performance microorganisms, and bioactive compounds.

Metric
Company Name	BRAIN Biotech AG	Biocatalysts
Symbol	BNN
MSH ID	COM:BRAIN-BIOTECH	COM:BIOCATALYSTS
Market	STOCKS	PRIVATE
Sector	Healthcare	Technology
Industry	Biotechnology	Biotechnology
Country	DE	GB
Stage
Employee Count	322	51
Website	brain-biotech.com	biocatalysts.com
LinkedIn		biocatalysts-ltd
Founders

Metric
Market Cap	53.08M
Enterprise Value
Monthly Web Traffic		6.81K
Web Traffic Growth		-0.35
Valuation
Raised Capital

Metric
Revenue	58.45M
Revenue (LTM)
Revenue (NTM)
Gross Profit	31.82M
EBITDA	-2.55M
Operating Income	-5.79M
Net Income	-8.74M
EPS	-0.40
Diluted EPS	-0.40
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.55
Operating Profit Margin	-0.11
EBITDA Margin	-0.04
Net Profit Margin	-0.15
Return on Equity	-0.37
Return on Assets	-0.12
Return on Capital Employed	-0.11

BNN

COM:BRAIN-BIOTECH

BRAIN Biotech AG

Last Close

3.15

25/11 09:24

Market Cap

50.25M

Beta: -

Volume Today

6.57K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-9.75
P/B Ratio	3.62
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.56
EV Multiple	-3.56

Metric
Days Sales Outstanding	65.06
Days Payables Outstanding	81.31
Days Inventory Outstanding	73.68
Operating Cycle	120.37
Cash Conversion Cycle	83.10
Asset Turnover	0.93

Metric
Operating Cash Flow	-4.46M
Free Cash Flow	-7.24M
Cash Flow to Debt
Operating Cash Flow/Sales	-0.07
Free Cash Flow Yield	-0.06

Metric
Cash & Equivalents	5.65M
Accounts Receivable	-1.40M
Inventory	10.27M
Goodwill	7.04M
Debt to Capitalization	0.67
Debt to Assets	0.42
Current Ratio	1.46
Quick Ratio	2.57

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue